Xie Laiping, Wang Yuhang, Wan Andi, Huang Lin, Wang Qing, Tang Wanyan, Qi Xiaowei, Hu Xiaofei
Department of Nuclear Medicine, Southwest Hospital, Army Medical University, Chongqing, China.
Department of Gastroenterology, Beijing Children's Hospital, Capital Medical University, Beijing, China.
Hum Vaccin Immunother. 2025 Dec;21(1):2460272. doi: 10.1080/21645515.2025.2460272. Epub 2025 Feb 4.
The approach of neoadjuvant therapy for breast cancer, which involves administering systemic treatment prior to primary surgery, has undergone substantial advancements in recent decades. This strategy is intended to reduce tumor size, thereby enabling less invasive surgical procedures and enhancing patient outcomes. This study presents a comprehensive bibliometric analysis of research trends in neoadjuvant therapy for breast cancer from 2009 to 2024. Using data extracted from the Web of Science Core Collection, a total of 3,674 articles were analyzed to map the research landscape in this field. The analysis reveals a steady increase in publication output, peaking in 2022, with the United States and China identified as the leading contributors. Key institutions, such as the University of Texas System and MD Anderson Cancer Center, have been instrumental in advancing the research on neoadjuvant therapy. The study also highlights the contributions of influential authors like Sibylle Loibl and Gunter von Minckwitz, as well as major journals such as the Journal of Clinical Oncology. Emerging research topics, including immunotherapy, liquid biopsy, and artificial intelligence, are gaining prominence and represent potential future directions for clinical applications. This bibliometric analysis provides critical insights into global research trends, key contributors, and future developments in the field of neoadjuvant therapy for breast cancer, offering a foundation for future research and clinical practice advancements.
乳腺癌新辅助治疗方法是指在初次手术前进行全身治疗，近几十年来该方法取得了重大进展。这一策略旨在缩小肿瘤大小，从而使手术侵入性更小，并改善患者预后。本研究对2009年至2024年乳腺癌新辅助治疗的研究趋势进行了全面的文献计量分析。利用从科学网核心合集提取的数据，共分析了3674篇文章，以描绘该领域的研究概况。分析显示，发表量稳步增长，在2022年达到峰值，美国和中国被确定为主要贡献者。德克萨斯大学系统和MD安德森癌症中心等关键机构在推动新辅助治疗研究方面发挥了重要作用。该研究还突出了西比尔·洛伊布尔和冈特·冯·明克维茨等有影响力的作者以及《临床肿瘤学杂志》等主要期刊的贡献。包括免疫疗法、液体活检和人工智能在内的新兴研究主题正日益突出，代表了临床应用的潜在未来方向。这项文献计量分析为乳腺癌新辅助治疗领域的全球研究趋势、关键贡献者和未来发展提供了重要见解，为未来的研究和临床实践进展奠定了基础。
